31465-35-7

Basic information

• Product Name: 4-(4-BROMOPHENOXY)ANILINE
• Synonyms: 4-(4-Bromophenoxy)aniline 97%
• CAS NO: 31465-35-7
• Molecular Formula: C₁₂H₁₀BrNO
• Molecular Weight: 264.12
• Product Categories: Amines;C11 to C38;Nitrogen Compounds
• Mol File: 31465-35-7.mol
• Article Data: 5

Chemical Properties

• Melting Point: 104-108 °C
• Boiling Point: 365.1°C at 760 mmHg
• Flash Point: 174.6°C
• Appearance: /
• Density: 1.479g/cm³
• Vapor Pressure: 1.61E-05mmHg at 25°C
• Refractive Index: 1.643
• Storage Temp.: 2-8°C
• PKA: 4.60±0.10(Predicted)
• CAS DataBase Reference: 4-(4-BROMOPHENOXY)ANILINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-BROMOPHENOXY)ANILINE(31465-35-7)
• EPA Substance Registry System: 4-(4-BROMOPHENOXY)ANILINE(31465-35-7)

Safety Data

• Hazard Codes: Xi
• Statements: 22-43
• Safety Statements: 36/37
• WGK Germany: 3
• Hazardous Substances Data: 31465-35-7(Hazardous Substances Data)

Usage

General Description

4-(4-Bromophenoxy)aniline is a chemical compound with the molecular formula C12H10BrNO. It is a white to light cream-colored solid with a molecular weight of 261.12 g/mol. 4-(4-BROMOPHENOXY)ANILINE is commonly used as an intermediate in the synthesis of various pharmaceuticals, agrochemicals, and organic compounds. It is also used as a dye intermediate and in the manufacturing of polymers and other organic products. 4-(4-Bromophenoxy)aniline is classified as a hazardous chemical and should be handled with care, as it can cause irritation to the skin, eyes, and respiratory system upon exposure.

InChI:InChI=1/C12H10BrNO/c13-9-1-5-11(6-2-9)15-12-7-3-10(14)4-8-12/h1-8H,14H2

Upstream product

• 21969-04-0 1-(4-nitrophenoxy)-4-bromobenzene 
• 100-00-5 4-chlorobenzonitrile 
• 101-55-3 4-Bromodiphenyl ether 
• 106-41-2 4-bromo-phenol 
• 620-88-2 4-nitrophenyl phenyl ether 
• 101-84-8 diphenylether 

Downstream Products

• 405175-85-1 [4-(4-amino-phenoxy)-phenyl]-phosphonic acid diethyl ester 
• 332897-73-1 4-oxo-4-((4-(4-bromophenoxy)phenyl)amino)butanoic acid 
• 333432-23-8 5-oxo-5-((4-(4-bromophenoxy)phenyl)amino)pentanoic acid 
• 13320-48-4 4-hydroxy-4'-bromodiphenyl ether 
• 6973-38-2 bis-(4-bromo-2-nitro-phenyl)-ether 
• 15211-97-9 (4-bromo-2-nitro-phenyl)-(4-bromo-phenyl)-ether 

Relevant articles and documents

C-H Amination of Arenes with Hydroxylamine

This Letter describes the development of a TiIII-mediated reaction for the C-H amination of arenes with hydroxylamine. This reaction is applied to a variety of electron-rich (hetero)arene substrates, including a series of natural products and pharmaceuticals. It offers the advantages of mild conditions (room temperature), fast reaction rates (30 min), compatibility with ambient moisture and air, scalability, and the use of inexpensive commercial reagents.

Synthesis, SAR and molecular docking study of novel non-β-lactam inhibitors of TEM type β-lactamase

The novel classes of acylated phenoxyanilide and thiourea compounds were investigated for their ability to inhibit TEM type β-lactamase enzyme. Two compounds 4g and 5c reveal the inhibition potency in micromolar range and show their action by non-covalent binding in the vicinity of the TEM-171 active site. The structure activity relationship around carbon chain length and different substituents in ortho- and para-positions of acylated phenoxyanilide as well as molecular modelling study has been performed.

Discovery of 1,2,4-triazole-1,3-disulfonamides as dual inhibitors of mitochondrial complex II and complex III

Respiratory chain succinate-ubiquinone oxidoreductase (SQR or complex II) and ubihydroquinone-cytochrome (cyt) c oxidoreductase (cyt bc1 or complex III) have been demonstrated as the promising targets of numerous antibiotics and fungicides. As a continuation of our research work on the development of new fungicides, a series of 1,2,4-triazole-1,3-disulfonamide derivatives with dual functions targeting both SQR and cyt bc1 were designed and synthesized by coupling diverse diphenyl ether moieties with triazolesulfonamide units. These newly synthesized compounds were characterized by elemental analyses, 1H NMR and ESI-MS spectrometry. The in vitro assay indicated that most of the synthesized compounds displayed good inhibition against porcine succinate-cytochrome reductase (SCR) with IC50 values ranging from 3.2 to 81.8 μM, revealing much higher activity than that of the commercial control amisulbrom whose IC50 value is 93.0 μM. Further evaluation against the respective SQR and cyt bc1 indicated that most compounds exhibited SQR-inhibiting activity as well as cyt bc1-inhibiting activity, but the inhibition potency against SQR is much higher than that against cyt bc1, showing that the SCR inhibition might be contributed greatly by the SQR inhibition. The further antibacterial evaluation against Xanthomonas oryzae pv. oryzae revealed that four compounds showed excellent potency at the concentration of 20 μg mL-1. In particular, compounds 6h and 6j exhibited much better antibacterial activity than the commercial control bismerthiazol in terms of their EC50. Impressively, 6j has an EC90 of 33.62 μg mL-1, more than 10-fold higher than that of bismerthiazol.